Age: 1.58
Sex: M
Vaccine: HIBV, MMR
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE; HCP reported vaccines were administered to multiple patients after a TE that occurred on 02JAN2024.; This non-valid spontaneous report was received from a medical assistance and refers to an unspecified number of patients of unknown age and gender.  The patients' medical history, concurrent conditions and concomitant therapies were not reported.  Since 21-JAN-2024, the patients were vaccinated with improperly stored doses of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) rHA (recombinant human albumin) injection, lot #X019302, expiration date: 14-JAN-2025, administered for prophylaxis (strength, and route of administration were not provided); haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) intramuscular injection, lot #W028536, expiration date: 12-MAY-2025, administered for prophylaxis (strength, and route of administration were not provided); measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) rHA (recombinant human albumin) injection, lot #W025567, expiration date: 14-AUG-2024, administered for prophylaxis (strength, and route of administration were not provided); and  varicella virus vaccine live (oka/merck) (VARIVAX) injection, lot #X010535, expiration date: 11-APR-2025 (also reported as 11-APR-2024), administered for prophylaxis (strength, and route of administration were not provided).  There were no adverse effects reported. Administered doses of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and varicella virus vaccine live (oka/merck) (VARIVAX) experienced the temperature excursion of 14 Fahrenheit degrees up to 46 Fahrenheit degrees for 29 minutes. There were no previous excursions reported.  Administered doses of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) experienced the temperature excursion of 47.6 Fahrenheit degrees for 29 minutes. There were no previous excursions reported.  This is a non-valid case due to the lack of patients' identifiers.  Follow up information has been received from an office coordinator (also reported as medical assistance) on 10-APR-2024.   The case is a valid case, concerning a male patient of 19-month-old.   Caller states she had no patients who received the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) or varicella virus vaccine live (oka/merck) (VARIVAX) , but did have patients for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) . Facility was a public clinic.  The patient's medical history included eustachian tube dysfunction bilateral, recurrent otitis media, hydrocele and hydronephrosis.   On 16-JAN-2024, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) ) administered in the right thigh subcutaneously; and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) given in left vastus lateralis (LVL) intramuscularly. On that same day, he also received diphtheria vaccine toxoid (+) pertussis vaccine acellular (+)tetanus vaccine toxoid (DTAP), hepatitis a vaccine inact and hib vaccine (dose, frequency, route, lot number and expiration date not reported) as prophylaxis.   This is one of the several cases created from the same source.